News | May 05, 2010

Treatment of Ventricular Tachycardia Using Magnetic Navigation Highlighted at HRS

May 5, 2010 – Catheter ablation of ventricular tachycardia (VT) is one of the fastest growing electrophysiology (EP) procedures, but requires the delivery of robust lesions for clinical success. Stereotaxis Inc. is starting a multicenter clinical study on VT treatment outcomes using its Niobe Magnetic Navigation System.

The prospective multicenter clinical effort, named "Study to Obliterate Persistent Ventricular Tachycardia" (STOP-VT), will be conducted at The Hospital of University of Pennsylvania, Methodist Hospital (Indianapolis), Na Holmoce Hospital (Prague), Loyola University Medical Center (Chicago), and Herzentrum Leipzig GmbH (Germany). During the upcoming 31st Annual Heart Rhythm Society (HRS) Scientific Sessions in Denver Petr Neuzil, M.D., PhD, from Na Holmoce Hospital in Prague, will present a poster detailing the early results of the STOP-VT study.

"Ablation of ventricular tachycardia is an excellent application for Stereotaxis magnetic navigation," said John Miller, M.D., professor of medicine, Krannert Institute of Cardiology, Indiana University School of Medicine. "Our experience has been that the precise intricate mapping and enhanced safety of magnetic navigation allows us to perform successful ablation of complex arrhythmias without the pitfalls associated with manual techniques."

During the upcoming HRS Scientific Sessions, additional VT outcome data will be presented by established Stereotaxis users. Hiroshi Nakagawa, M.D., PhD, co-director of the Heart Rhythm Institute at the University of Oklahoma Health Sciences Center and an expert on contact force and lesion formation, will present a paper entitled, "Substrate Ablation of Scar Ventricular Tachycardia Using Magnetic Catheter Maneuvering System." In addition to the VT data, several Stereotaxis users from around the world will present clinical results related to atrial fibrillation (AF), pediatric and congenital arrhythmia, supraventricular tachycardia (SVT), atrial flutter, and use with implantable devices through a series of presentations and posters.

More than 130 hospitals have adopted magnetic navigation for a growing number of complex ablation cases in all four chambers of the heart.

For more information: www.stereotaxis.com


Related Content

News | Cardiovascular Clinical Studies

Aug. 4, 2026 — Abbott has completed enrollment in its TECTONIC coronary artery disease (CAD) Intravascular Lithotripsy ...

Home August 06, 2026
Home
News | Cardiovascular Clinical Studies

June 25, 2026 — Johnson & Johnson has announced the initiation of its Skyward investigational device exemption (IDE) ...

Home June 25, 2026
Home
News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
Subscribe Now